Iterum Therapeutics plc
ITRM
$0.99
-$0.007-0.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.37% | 6.80% | -4.08% | -12.79% | -30.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.99% | -60.61% | -39.82% | 11.49% | 43.00% |
| Operating Income | 63.99% | 60.61% | 39.82% | -11.49% | -43.00% |
| Income Before Tax | 36.33% | 35.02% | 1.08% | 50.51% | 31.05% |
| Income Tax Expenses | -53.16% | -60.85% | -37.59% | 340.25% | 18,033.33% |
| Earnings from Continuing Operations | 36.59% | 35.44% | 1.75% | 49.70% | 29.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.59% | 35.44% | 1.75% | 49.70% | 29.99% |
| EBIT | 63.99% | 60.61% | 39.82% | -11.49% | -43.00% |
| EBITDA | 64.33% | 59.73% | 38.42% | -14.79% | -47.10% |
| EPS Basic | 62.29% | 55.67% | 17.77% | 55.81% | 35.96% |
| Normalized Basic EPS | 62.13% | 55.38% | 17.17% | 56.56% | 36.95% |
| EPS Diluted | 62.22% | 55.61% | 17.77% | 55.81% | 35.96% |
| Normalized Diluted EPS | 62.13% | 55.38% | 17.17% | 56.56% | 36.95% |
| Average Basic Shares Outstanding | 78.30% | 51.83% | 27.96% | 16.05% | 10.44% |
| Average Diluted Shares Outstanding | 78.30% | 51.83% | 27.96% | 16.05% | 10.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |